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This paper presents to the surgical community an unusual and often ignored cause of gastrointestinal bleeding. Hemophagocytic
syndrome or hemophagocytic lymphohistiocytosis (HLH) is a rare medical entity characterized by phagocytosis of red blood cells,
leucocytes, platelets, and their precursors in the bone marrow by activated macrophages. When intestinal bleeding is present, the
management is very challenging with extremely high mortality rates. Early diagnosis and treatment seem to be the most important
factors for a successful outcome. We present two cases and review another 18 from the literature.
1. Introduction
Gastrointestinal (GI) bleeding is a common cause for hospital
admission to surgical wards. In westernized countries, the
annual incidence of upper GI bleeding is approximately 100
−200/100,000 and for lower GI bleeding 20–30/100,000. The
estimated mortality ranges from 6% to 10% for upper GI
bleeding and from2% to 4% for lowerGI bleeding [1–4].Most
episodes of lower GI bleeding resolve spontaneously, while
others can be treated endoscopically or by interventional
radiology. A minority of patients become hemodynamically
unstable and require emergency surgery. In such cases, the
source of bleeding is not always clear and the surgeon
may face the difficult decision to perform extensive colonic
resections, at a price of significant mortality rates (up to
25%), without the certitude of controlling the source of
bleeding [5–7].Themost frequent causes of lowerGI bleeding
are diverticulosis and arterial-venous malformations. Other
frequent causes are colitis, neoplasms, inflammatory bowel
disease, and hemorrhoids [8, 9].
In this paper, we report the dramatic cases of two patients
who presented massive lower GI bleeding originating from
diffuse GI mucosal ulcerations secondary to acute Epstein
Barr virus (EBV) proliferation and hemophagocytic lympho-
histiocytosis (HLH) and review the literature for GI bleeding
associated with this rare syndrome.
2. Case 1
A 26-year-old male patient, treated for Crohn’s disease with
azathioprine (150mg/day) for 3 years, was admitted to the
ENT department of a community hospital for treatment of a
febrile pharyngitis with 10-day cefuroxime. Lab tests revealed
leucopenia (2.7 g/L, 89% neutrophils, 8% monocytes) and a
mild elevation of the liver enzymes. Clinically and radiolog-
ically, splenomegaly was present. An active EBV infection
(IgG and IgM positive) was diagnosed on hospital day 7
and treatment with valacyclovir (1 gr × 3/day) was started.
At the same day, the patient presented massive lower GI
bleeding requiring admission to the ICU. The initial emer-
gency colonoscopy revealed severe pancolitis with multiple
ulcerations which was attributed to a flare of Crohn’s colitis.
Three days later (day 10), despite multiple transfusions, he
became hemodynamically unstable due to continuous bleed-
ing (CRP 121mg/L, procalcitonin 1.21mcg/L). The patient
was therefore transferred to our University Hospital. Upon
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arrival, he developed a hypovolemic shock requiring massive
blood transfusions and an emergent total colectomy with
ileostomy was performed. Broad-spectrum antibiotherapy
with piperacillin/tazobactam (4.5 gr × 4/day) and prednisone
50mg/d was initiated in the immediate postoperative period.
A thoracic CT-scan showed bilateral pulmonary infiltrates,
which were attributed to transfusion related acute lung injury
(TRALI). Blood tests revealed pancytopenia and increasing
levels of ferritin (2600mg/L) thought to be due to the
combination of inflammation and azathioprine treatment.
Three days later (day 13), the patient was transferred back to
the ICU of the first hospital.
There, severe mononucleosis with persistent high EBV
viremia despite antiviral treatment was diagnosed. The
patient presented multiple episodes of upper GI bleeding
that required further repeated transfusions.Upper endoscopy
revealed hemorrhagic gastroduodenitis with multiple bleed-
ing ulcers. Blood tests revealed a further increase of ferritin
(up to 15,000𝜇g/L) and LDH (up to 4000U/L) together
with worsening pancytopenia and finally agranulocytosis.
Repeated bone morrow biopsies finally revealed HLH with
macrophage activation syndrome and hemophagocytosis.
The patient was treated with high doses of steroids alone and
exhibited transient improvement but eventually expired fol-
lowing multiple organ failure 12 days later. The biopsies from
gastric, duodenal, and colonic tissues all revealed an EBV-
associated lymphoid proliferation. The autopsy concluded to
a generalized EBV infection with lymphoid proliferation of
the entire digestive tube and multiple organs, with associated
secondary macrophage activation syndrome.
3. Case 2
A 61-year-old male patient in good general health presented
with an episode of significant lower GI bleeding. The patient
had had a minor similar episode 4 months ago. One month
ago, he had felt fatigue and repeated episodes of fever without
any other specific symptoms.
Upon primary admission to another hospital, the patient
was tachycardic and slightly hypotensive but improved after
massive hydration and was transferred to our center. An
upper endoscopy revealed only a small Mallory-Weiss type
ulcer, which seemedunlikely to have been the source of bleed-
ing. An angio-CT-scan of the abdomen revealed extensive
diverticulosis with signs of transverse colitis but without a
precise source of bleeding. The patient was treated conserva-
tively but, in the following days, he developed fever and an
important inflammatory syndrome (CRP 253mg/L, normal
leucocyte count) with rhabdomyolysis, acute renal failure,
and high levels of LDH (1451U/L) and ferritin (1200mg/L)
along with anemia and progressive thrombocytopenia.Three
days after his admission, he once again became hemodynam-
ically unstable due to recurrent massive low GI bleeding.
From the time of patient’s entry to that point, he had received
a total of 10 units of RBC. Emergency laparotomy with
intraoperative colonoscopy and enteroscopy was performed.
Findings were an important inflammatory status around the
transverse colon, a small intestinal perforation at the distal
ileum, and 10–20 ulcerated inflammatory lesions in the ileum,
one of which was actively bleeding. A resection of 60 cm of
ileumwas carried out and the patientwas admitted to the ICU
for postoperative surveillance. Histopathology of the ileum
revealed a high grade NK-T lymphoma Epstein Barr virus
(EBV) positive.
Two days after surgery, the patient became septic. A tho-
racoabdominal CT-scan showed bilateral pleural effusions
but no specific septic source. In the absence of radiolog-
ical signs that would explain the patient’s septic status, a
“second look” laparotomy was performed but no source of
sepsis was identified. Subsequently, the patient’s condition
deteriorated rapidly. He developed disseminated intravascu-
lar coagulation and finally a new episode of GI bleeding.
Based on the above listed observations together with ferritin
levels at 15000mcg/L, HLH was suspected and a treatment
with CHOP regimen (cyclophosphamide 750mg/m2 day
1, doxorubicin 50mg/m2/day 1, Oncovin 1.4mg/m2/day 1,
and prednisone 60mg/m2/day 1 to 5) plus etoposide was
initiated. No bone marrow biopsies were performed as
death due to hemodynamic instability followed the next day.
Autopsy revealed a NK-T extranasal EBV + lymphoma with
intestinal localization. Bone marrow presented with massive
hemophagocytosis without any evidence of tumor infiltration
(see Figure 1).
4. Discussion
Hemophagocytic lymphohistiocytosis (HLH) or hemopha-
gocytic syndrome represents a rare pathophysiologic entity
characterized by a hyperinflammatory state, cytokine dereg-
ulation, impaired function of cytotoxic T-cells (CTL), and
natural killer (NK) cells in addition to hemophagocytosis
(i.e., phagocytosis by activated macrophages of red blood
cells, leucocytes, platelets and their precursors in the blood
marrow, spleen, or other lymphoid organs) [23, 24].
There is an inherited or familial form (FHLH) and an
acquired or secondary HLH [25]. The FHLH incidence is
estimated to be 0.12/100.000 children per year and has its
onset under the age of 1 year in the majority (70%–80%)
of patients [26]. Patients with inherited immune deficiencies
like the Chediak-Higashi syndrome as well as the X-linked
proliferative syndrome are also at high risk to develop HLH.
Secondary HLH may occur at all ages [24] and is usually
diagnosed in association with malignant (mostly with cuta-
neous or anaplastic lymphomas), autoimmune, or infectious
diseases. Infection associated with HLH is mostly associated
with viral infections of the herpes group, in particular EBV
and cytomegalovirus (CMV) [23, 25]. EBV induced HLH
may mimic or favor T-cell lymphoma and other EBV-linked
lymphoproliferative disorders [23]. Other nonviral agents
such as bacteria, mycobacteria, protozoa, and fungi canmore
rarely trigger HLH [24]. Cases of HLH after immunization
with measles vaccine, probably in predisposed patients, have
also been documented [27].
The dominant clinical characteristics of HLH are persis-
tent fever, usually unresponsive to antibiotics, splenomegaly
and/or hepatomegaly, lymphadenopathies, icterus, rash,
anorexia, and GI bleeding. Neurological symptoms, such as
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Figure 1: Hemophagocytosis in the bone marrow of Case 2.
seizures or cranial nerve palsies, are rare in the acquired form
but are found in up to 1/3 of patients with FHLH [25, 28–30].
Laboratory findings include cytopenia, in at least two
cell lineages, elevated hemolysis parameters, hypofibrinogen-
emia (and possibly disseminated intravascular coagulation),
hypertriglyceridemia, and hyperferritinemia. Inflammatory
markers like the C-reactive protein may be quite high due to
the syndrome’s inflammatory state. Special markers include
increased soluble CD25 (alpha-chain of the interleukin (IL-2)
receptor) reflecting increased T lymphocytes activation and
turnover and profoundly decreased or absent NK cell activity
[24, 29, 31]. The Th1/Th2 biomarker is another recently
developed diagnostic tool [32].
Diagnosis in patients with clinical suspicion of HLH
requires bone marrow aspiration and biopsy. Positive biop-
sies reveal normal maturation of all cell lineages, normal
or increased cellularity, and infiltration with macrophages/
histiocytes associated with hemophagocytosis [25]. How-
ever, hemophagocytosis is often initially absent, requiring a
repeated exam [24]. Due to the insidious nature of HLH,
diagnosis is difficult, needs to be based on a combination of
clinical and biological criteria, and is frequently established
after the patient’s death [22, 25, 33].
Infections must be actively sought as they may be the
trigger of the syndrome and represent a treatable cause.
Patients should be tested for EBV, CMV, herpes simplex, and
adenovirus [24]. Screening for less frequent infectious agents,
inherited immune deficiencies, and underlying malignancies
should be done according to clinical suspicion.
HLH, whether acquired or familial, is a severe condition
and, if left untreated, can lead to rapid deterioration and
death. There is no high level evidence to guide treatment;
the most widely accepted strategy is aggressive systemic
therapy with various combinations of immunosuppressive
and chemotherapeutic agents, along with the treatment of
the underlying causes, if identified. For the severe forms of
the FHLH, hematopoietic stem cell transplantation is cur-
rently considered to be the only curative option [32]. FHLH
therapies with antithymocyte globulin, steroids, cyclosporin
A, and intrathecal methotrexate to pediatric patients have
been reported with 73% rapid and complete response [30].
Due to the lack of studies in the adult population, patients
are usually treated with a regimen adapted from pediatric
protocols [29]. For adult patients with HLH secondary to
pathogens other than EBV, supportive care and treatment of
the underlying infection are associatedwith recovery in 60%–
70% [34]. EBV-associated HLH is almost universally fatal
if untreated, with death resulting usually from multiorgan
failure [31, 35].
The goal of this paper is to raise awareness among
surgeons about the rare medical entity of HLH, which may
present as a highly life threatening form of GI bleeding. In
both cases presented in this paper, the surgeonwas faced with
a clinical picture of severe GI bleeding. These patients had
presented a series of systemic clinical and laboratory findings
compatible with HLH (fever unresponsive to antibiotics,
splenomegaly, EBV infection, cytopenia, and high ferritin
levels) earlier in the course of their illness, but diagnosis of
HLH was not suspected until late. Surgical therapy for the
GI bleeding was challenging in both cases as the bleeding
source had not been localized precisely preoperatively. In the
first patient, total colectomy was performed, but bleeding
recurred, possibly from the documented coexisting gastro-
duodenal ulcerations. In the second patient, intraoperative
colonoscopy and enteroscopy helped localize the source and
guide the extent of the resection, but bleeding recurred as
well.The role of surgery cannot be denied in the acute setting
of life threatening GI bleeding. However, in these cases,
earlier diagnosis and medical treatment of HLH might have
prevented fatal recurrence.
The true incidence of GI bleeding in association with
HLH is hard to estimate. Guo et al., in a retrospective analysis
of 41 children with HLH, reported a rate of 12.2% [36]. In our
review of the literature on HLH with associated GI bleeding,
we found only a few other case reports (Table 1). Similar to
our two cases, mortality was very high (12 deaths out of 18)
and almost always secondary to uncontrollable GI bleeding.
Of course, the severity of bleeding in this small review may
be overrated due to selection and publication bias.The origin
of bleeding can be localized throughout the GI tract. Our
two patients bled form the colon, the small bowel, and the
stomach. The bleeding source can be diffuse or from linear
isolated ulcers. These gastrointestinal lesions are secondary
to transmural lymphohistiocytic infiltration of macrophages
as reported in histological findings [22], which in addition to
bleeding may lead to perforation, as in one of our patients.
Septic complications may be masked from the underlying
hyperinflammatory state caused by HLH. Emergent surgery
for intestinal resections or embolizationwas part of successful
treatment in some reports [15, 20, 36]; in others, similar to our
patients, it did not help control bleeding definitively [11, 19,
20, 22]. Administration of recombinant activated factor VII
seemed to provide short temporary but no definitive control
of bleeding in some reports [22, 37].
Hemophagocytic lymphohistiocytosis (HLH) is an elu-
sive medical entity, difficult to diagnose. It may be present as
life threatening GI bleeding and pose a challenging clinical
problem to the surgeon. Associated cytopenia, high ferritin,
and low fibrinogen levels, in combination with symptoms
and signs such as fever, hepatosplenomegaly, skin rash, and
lymphadenopathies, should raise suspicion early. Viral (EBV,
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CMV, and herpes simplex virus) and other (Mycobacterium
tuberculosis and Mycoplasma pneumonia) infections should
be looked for as they may represent treatable causes. Treat-
ment requires a multidisciplinary approach and surgery may
provide a temporary solution for GI bleeding or perforation,
but early diagnosis and systemic therapy are the only hope for
cure.
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